Chimerix reports Q4 EPS (25c), consensus (28c)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 21 2025
0mins
Q4 Revenue Report: Chimerix reported a Q4 revenue of $57,000, significantly below the consensus estimate of $310,600.
FDA Acceptance and Acquisition: The FDA's acceptance of the dordaviprone NDA is seen as a crucial milestone for Chimerix, with CEO Mike Andriole highlighting the positive impact of the pending acquisition by Jazz on their mission to deliver the drug to patients in need.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
